<DOC>
	<DOC>NCT01052506</DOC>
	<brief_summary>The primary objective of the study is to evaluate the safety and tolerability of single dose of BIIB033 administered to healthy adult volunteers.</brief_summary>
	<brief_title>BIIB033 Single Ascending Dose Study in Healthy Volunteer Subjects</brief_title>
	<detailed_description>BIIB033 is an investigational product being developed to promote remyelination in subjects with multiple sclerosis (MS). This healthy volunteer study will evaluate safety and tolerability of a single dose of BIIB033.</detailed_description>
	<criteria>Must be in good health BMI of 1830kg/m2 Contraception required for at least 6 months after study drug administration History of clinically significant disease or lab values Females of childbearing potentials Contraindication to brain MRI and/or lumbar puncture Treatment with any prescription medication within the 28 days prior to study entry Treatment with any overthecounter products, including herbal and/or alternative health preparations and procedures within the 14 days prior to study entry Regular use of any tobacco product within 3 months prior to study entry</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Human volunteers</keyword>
</DOC>